BioNTech, Pfizer stocks rally after first participants in U.S. trial of COVID-19 vaccine were dosedMarket Watch • 05/05/20
Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development ProgramGlobeNewsWire • 05/05/20
Pfizer and BioNTech Complete Dosing of First Group in Coronavirus Vaccine TrialThe Motley Fool • 04/29/20
BioNTech and Pfizer announce completion of dosing for first cohort of Phase 1/2 trial of COVID-19 vaccine candidates in GermanyGlobeNewsWire • 04/29/20
BioNTech and Pfizer announce regulatory approval from German authority Paul-Ehrlich-Institut to commence first clinical trial of COVID-19 vaccine candidatesGlobeNewsWire • 04/22/20
Pfizer, BioNTech, Arcturus Share Timelines For Human Testing As COVID-19 Vaccine Development IntensifiesBenzinga • 04/09/20
Covid Report: Pfizer Selects Lead Coronavirus Drug; Gilead Updates TestsInvestors Business Daily • 04/09/20
Pfizer and BioNTech Aim to Start Testing Coronavirus Vaccines in Humans by Late AprilThe Motley Fool • 04/09/20
Will the Pfizer-BioNTech Collaboration Be a Winner in the Fight Against COVID-19?24/7 Wall Street • 04/09/20
Pfizer discloses $185 million upfront payment to BioNTech for COVID-19 vaccine programMarket Watch • 04/09/20
Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine DevelopmentGlobeNewsWire • 04/09/20